AAM Calls on FTC to Investigate PBM Business Practices
Generic Manufacturers Ask the DOJ and the FTC to Investigate Market Abuses by Buying Groups
Seniors Are Still Missing Out on Savings in Medicare Part D
Generic Prices Are Falling, But Seniors Are Paying More for Generic Drugs. What’s Happening Here?
2021 U.S. Generic and Biosimilar Medicines Savings Report
Sidelined: How Seniors Miss Out On Savings Available Through Generic Substitution
Access Denied: Why New Generics Are Not Reaching America’s Seniors
AAM Securing Sustainable Markets
Abuse of the patent system is keeping drug prices high for patients
The Medicaid Generics Penalty: A Primer
